AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00241475
- Locations
- 🇫🇮
Research Site, Helsinki, Finland
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
Terminated
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00241462
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
Open Label Arimidex in Gynecomastia
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00241436
- Locations
- 🇺🇸
Research Site, Jacksonville, Florida, United States
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 556
- Registration Number
- NCT00241527
- Locations
- 🇬🇧
Research Site, Yoxall, United Kingdom
🇸🇪Sweden, Gävle, Sweden
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 808
- Registration Number
- NCT00241540
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 276
- Registration Number
- NCT00241553
- Locations
- 🇬🇧
Research Site, Yoxall, United Kingdom
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 334
- Registration Number
- NCT00241514
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00241501
- Locations
- 🇮🇹
Research Site, Roma, Italy
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00241423
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2008-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1362
- Registration Number
- NCT00241488
© Copyright 2024. All Rights Reserved by MedPath